---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Bruton tyrosine kinase inhibitors"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Bruton tyrosine kinase inhibitors. Topics: Remibrutinib: FDA-approved indication, dosage, and surgical interruption; Remibrutinib: mechanism of action; REMIX-1 and REMIX-2: design and Week 12 efficacy in the prescribing information; REMIX-1 and REMIX-2: Week 12 UAS7 outcomes and adverse events; 8 further topics. 12 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/bruton-tyrosine-kinase-inhibitors"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Bruton tyrosine kinase inhibitors

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Bruton Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

### Remibrutinib: FDA-approved indication, dosage, and surgical interruption

> “RHAPSIDO® is a kinase inhibitor indicated for adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of:”
> “chronic spontaneous urticaria (1)”
> “The recommended dosage is 25 mg taken orally twice daily with or without food.”
> “Interrupt treatment with RHAPSIDO for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

### Remibrutinib: mechanism of action

> “Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton’s tyrosine kinase (BTK).”
> “Remibrutinib inhibits mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators, mediated by pathogenic IgE or IgG directed against the FcεR1 or IgE.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### REMIX-1 and REMIX-2: design and Week 12 efficacy in the prescribing information

> “The efficacy of RHAPSIDO for chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment was evaluated in two identical, 52-week, multi-center, randomized, double-blind, placebo- controlled clinical trials (REMIX-1 [NCT05030311] and REMIX-2 [NCT05032157]).”
> “The co-primary endpoints were absolute change from baseline in ISS7 and HSS7 at Week 12.”
> “Secondary endpoints included proportion of patients who achieved UAS7 ≤6 at Weeks 2 and 12, and the proportion of patients who achieved complete absence of itch and hives (UAS7 = 0) at Week 12.”
> “In both REMIX-1 and REMIX-2 studies, the co-primary and all secondary endpoints showed statistically significant improvement in itch and hives symptoms in patients treated with RHAPSIDO compared to patients treated with placebo.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
| --- | --- | --- | --- | --- |
| LS mean (SE) change in ISS7 | “-9.52 (0.34)” | “-6.89 (0.47)” | “-8.95 (0.34)” | “-5.72 (0.45)” |
| LS mean (SE) change in HSS7 | “-10.47 (0.40)” | “-6.86 (0.55)” | “-10.47 (0.39)” | “-6.00 (0.53)” |
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

| Treatment difference versus placebo at Week 12 | REMIX-1 | REMIX-2 |
| --- | --- | --- |
| UAS7 difference in LS mean (SE) | “-6.22 (1.14)” | “-7.68 (1.14)” |
| UAS7 95% CI for difference | “-8.45, -4.00” | “-9.91, -5.46” |
| UAS7 ≤6 treatment difference (95% CI) | “25.44” “16.48, 34.39” | “27.61” “19.14, 36.08” |
| UAS7 = 0 treatment difference (95% CI) | “20.55” “13.35, 27.75” | “21.60” “15.10, 28.10” |

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

> “Multiple imputation techniques were implemented for missing data.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-4"></a>

### REMIX-1 and REMIX-2: Week 12 UAS7 outcomes and adverse events

> “A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive either remibrutinib (313 and 300 patients, respectively) or placebo (157 and 155 patients, respectively).”
> “The remibrutinib group had a significantly greater decrease in the UAS7 at week 12 than the placebo group (least-squares mean [±SE] change, -20.0±0.7 vs. -13.8±1.0 [P<0.001] in REMIX-1 and -19.4±0.7 vs. -11.7±0.9 [P<0.001] in REMIX-2), which appeared to be sustained through week 24.”
> “At week 12, significantly more patients in the remibrutinib group than in the placebo group had a UAS7 of 6 or lower (REMIX-1, 49.8% vs. 24.8% [P<0.001]; REMIX-2, 46.8% vs. 19.6% [P<0.001]) and a UAS7 of 0 (REMIX-1, 31.1% vs. 10.5% [P<0.001]; REMIX-2, 27.9% vs. 6.5% [P<0.001]).”
> “The percentages of patients with any adverse event and with serious adverse events were similar in the remibrutinib group and the placebo group, although a higher percentage of patients in the remibrutinib group than in the placebo group had petechiae (3.8% vs. 0.3% in the combined groups).”
> “Funded by Novartis Pharmaceuticals;”

Source: [Metz et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40043237/)

<a id="topic-2.2.2.1.4-5"></a>

### REMIX-1 and REMIX-2: Week 52 efficacy and safety

> “Patients were randomized 2:1 to receive oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks).”
> “At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score (mean [95% confidence interval], REMIX-1: -23.22 [-24.78, -21.66]; REMIX-2: -22.98 [-24.51, -21.44]), with similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning).”
> “Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis.”

Source: [Giménez-Arnau et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41115533/)

<a id="topic-2.2.2.1.4-6"></a>

### Pooled REMIX-1 and REMIX-2: disease control, sleep, and quality of life through Week 52

> “To evaluate the impact of remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, on disease control, sleep, and QoL in CSU.”
> “REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were phase 3, double-blind, placebo-controlled studies in adults with CSU who remained symptomatic despite receiving second-generation H1-antihistamines.”
> “The pooled analysis included 606 and 306 patients receiving remibrutinib and placebo, respectively.”
> “Within 1 week of starting remibrutinib, greater improvements in mean (SD) change from baseline (CFB) compared with placebo were noted in urticaria activity (CFB-Urticaria Activity Score: -11.8 [9.9] and -3.6 [7.6]) and sleep (CFB-Sleep Interference Score: -4.9 [4.9] and -1.9 [4.1]).”
> “Across assessments, responses were sustained through week 52 with remibrutinib, and comparable improvements were observed in those who transitioned to remibrutinib.”

Source: [Mosnaim et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42297099/)

<a id="topic-2.2.2.1.4-7"></a>

### Remibrutinib: bleeding risk, live vaccines, and adverse reactions in the prescribing information

> “In clinical trials, mucocutaneous-related bleeding occurred in 9% of patients who received RHAPSIDO”
> “Use of antithrombotic agents concomitantly with RHAPSIDO may further increase the risk of bleeding”
> “The use of live and live-attenuated vaccines should be avoided in patients receiving RHAPSIDO.”
> “The most common adverse reactions (incidence >3%) were nasopharyngitis, bleeding, headache, nausea and abdominal pain.”
> “In the pooled safety population (REMIX-1 and REMIX-2), bleeding occurred in 9% of patients treated with RHAPSIDO compared to 2% in the placebo group during the 24-week controlled treatment period [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Drug Interactions (7.2)]. Petechiae (4%) and contusion (2%) were the most commonly reported reactions in patients treated with RHAPSIDO. No severe bleeding reactions occurred.”
> “Similar safety findings were observed through Week 52”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-8"></a>

### Pooled REMIX-1 and REMIX-2 safety: bleeding, infections, cytopenia, and hepatic disorders

> “This was a pooled analysis of REMIX-1 and REMIX-2 consisting of a 24-week, randomized, double-blind, placebo-controlled period, followed by a 28-week open-label treatment period.”
> “AE frequencies and risk differences (95% CI) for remibrutinib (n = 606) versus placebo (n = 306) were as follows: any AE 64.9% versus 64.7%, difference 0.1% (-6.4% to 6.7%); bleeding (including laboratory abnormalities) 10.6% versus 5.2%, difference 5.3% (1.6% to 8.7%); infections 33.5% versus 34.3%, difference -0.8% (-7.4% to 5.6%); cytopenia AEs 3.6% versus 2.0%, difference 1.7% (-0.7% to 3.8%); hepatic disorders 3.3% versus 4.9%, difference -1.6% (-4.6% to 1.1%).”
> “Imbalance in bleeding was due to petechia and similar mucocutaneous events (predominantly mild, none severe) occurring in 9.1% of patients on remibrutinib versus 2.0% of patients on placebo.”
> “Findings during the entire study period were consistent with those in the controlled period.”

Source: [Giménez-Arnau et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42242425/)

<a id="topic-2.2.2.1.4-9"></a>

### Remibrutinib: drug interactions and hepatic impairment in the prescribing information

> “Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors.”
> “Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers.”
> “No data are available on concomitant use of RHAPSIDO with anticoagulants. The concomitant use of RHAPSIDO and anticoagulants was not allowed in clinical studies. Use of the antiplatelet agents, acetyl salicylic acid at doses up to 100 mg daily or clopidogrel up to 75 mg daily, was allowed in the RHAPSIDO clinical studies.”
> “Avoid use of RHAPSIDO in patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B, and C)”
> “The safety and effectiveness of RHAPSIDO have not been established in pediatric patients.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-10"></a>

### International guideline: remibrutinib suggested as add-on after high-dose H1-antihistamines

> “We suggest using remibrutinib”
> “as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.”
> “The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high‐dose antihistamine and omalizumab treatment.”
> “25 mg twice daily will most likely be recommended as the treatment dose”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.4-11"></a>

### Rilzabrutinib: RILECSU phase 2 Week 12 results in antihistamine-refractory CSU

> “What is the efficacy and risk profile of rilzabrutinib, an oral reversible covalent Bruton tyrosine kinase inhibitor, in adults with antihistamine-refractory chronic spontaneous urticaria (CSU)?”
> “The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension.”
> “Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo.”
> “The primary analysis population included only the 143 omalizumab-naive patients.”
> “Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, −9.21 vs −5.77; difference, −3.44 [95% CI, −6.25 to −0.62]; P  = .02) and UAS7 (LS mean, −16.89 vs −10.14; difference, −6.75 [95% CI, −12.23 to −1.26]; P  = .02).”
> “Further research is needed to determine long-term efficacy and potential harms.”

Source: [Giménez-Arnau et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019677/)

<a id="topic-2.2.2.1.4-12"></a>

### Rilzabrutinib adverse events: diarrhea, nausea, and headache

> “adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache.”
> “The most frequent treatment-emergent AEs with rilzabrutinib, 800 mg/d, and rilzabrutinib, 1200 mg/d, were diarrhea and nausea, with most events reported as mild, and none reported as severe.”

Source: [Giménez-Arnau et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019677/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
